吡柔比星联合用药的抗肿瘤疗效综述
|
摘要
本综述整理了近五年吡柔比星联合用药相关文献,综述了吡柔比星与药物和非药物联用对疾病的治疗及其疗效。结果发现吡柔比星联用主要用于治疗膀胱癌、乳腺癌、血液疾病,主要联用方式有药物联用和非药物联用,且吡柔比星联用能起到增强疗效、降低药量、减少不良反应的效果。
This review summarized the literature on the combined treatments of Pirarubicin in the past five years, and reviewed the treatments and efficacies of Pirarubicin in combination with drugs and non-drugs. It was found that Pirarubicin was mainly used for the treatment of bladder cancer, breast cancer and blood diseases. The main combinations were Pirarubicin with drugs and non-drugs. Moreover, the combined treatment of Pirarubicin could enhance the efficacy and decrease the dose, and reduce the effects of adverse reactions.
This review summarized the literature on the combined treatments of Pirarubicin in the past five years, and reviewed the treatments and efficacies of Pirarubicin in combination with drugs and non-drugs. It was found that Pirarubicin was mainly used for the treatment of bladder cancer, breast cancer and blood diseases. The main combinations were Pirarubicin with drugs and non-drugs. Moreover, the combined treatment of Pirarubicin could enhance the efficacy and decrease the dose, and reduce the effects of adverse reactions.
引文
[1]Aoki S,Tsukada N,Nomoto N,et al. Effect of pirarubicin for elderly patients with malignant lymphoma[J]. J Exp Clin. Cancer Res,1998,17(4):465-470.
[2]Kudo K,Kojima S,Tabuchi K,et al. Prospective study of a pirarubicin,intermediate-dose cytarabine,and etoposide regimen in children with Down syndrome and acute myeloid leukemia:the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol,2007,25(34):5442-5447.
[3]Robert J,Monnier A,Poutignat N,et al. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients[J]. Cancer Chemother Pharmacol,1991,29(1):75-79.
[4]Ito A,Shintaku I,Satoh M,et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin(THP)in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma:the THP Monotherapy Study Group Trial[J]. J. Clin. Oncol,2013,31(11):1422-1427.
[5]YamamotoY,NasuY,SaikaT,etal.Theabsorptionof pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer[J]. BJU Int,2000,86(7):802-804.
[6]杨玉龙,宋炳生.新型抗肿瘤药吡柔比星(THP)国内临床应用概况[J].华西药学杂志,1998,13(3):168-174.
[7]Li K,Chen X,Liu C,et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells[J]. Biochem Biophys Res Commun,2015,460(2):380-385.
[8]葛波,宋亚辉,张旭,等.吡柔比星诱导人膀胱癌T24细胞凋亡及其作用机制[J].中华实验外科杂志,2014,31(10):2235-2237.
[9]欧俐苹,杜红飞,吕长坤,等.吡柔比星通过PLCε-Bcl-2通路抑制膀胱癌细胞增殖[J].第二军医大学学报,2014,35(7):708-713.
[10]李鹏程,李飞,宋亚辉,等.吡柔比星对膀胱癌EJ细胞增殖及Livin和Caspase-3表达的影响[J].医学研究生学报,2015,28(3):255-259.
[11]卜强,曾明辉,蒋华,等.吡柔比星联合雷公藤甲素对人膀胱癌T24细胞生长的影响[J].肿瘤,2014,34(6):514-519.
[12]吕长坤,万雪莲,马菲菲,等. HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖[J].重庆医科大学学报,2015,40(2):234-238.
[13]宋兆录,刘镇,彭传真,等.术中黏膜下注射与术后即刻灌注吡柔比星预防表浅性膀胱癌术后复发的疗效比较[J].现代泌尿外科杂志,2011,16(1):45-46.
[14]陶炅华,江秀.吡柔比星联合羟基喜树碱对预防膀胱癌电切术后复发的疗效[J].检验医学与临床,2015,12(4):546-547.
[15]蓝汉荣,胡万胜.不同手术方案联合吡柔比星膀胱灌注化疗在浅表性膀胱癌患者中的应用比较[J].中国当代医药,2015,22(8):68-70.
[16]丁宝军,刘成,刘多,等.二次电切联合盐酸吡柔比星膀胱灌注治疗高危非肌层浸润性膀胱尿路上皮癌疗效观察[J].现代医药卫生,2014,30(19):2908-2910.
[17]武广平,秦玉波,乔卫东,等.吡柔比星膀胱灌注联合腔镜技术对膀胱继发性原位癌定位诊断及治疗的效果观察[J].山东医药,2011,51(46):47-48.
[18]王磊,刘致中,赵海涛,等.非肌层浸润性膀胱癌TURBT术后黏膜下注射吡柔比星联合丝裂霉素灌注的疗效观察[J].临床泌尿外科杂志,2014,29(2):125-127.
[19]张冲,杨鹏,刘振湘. RevoLix 2μm激光联合吡柔比星在非肌层浸润性膀胱癌治疗中的应用[J].现代泌尿生殖肿瘤杂志,2014,6(3):137-139.
[20]厉波,厉彦卓,武广平,等.高能聚焦超声联合吡柔比星姑息性治疗膀胱癌(附18例报告)[J].临床泌尿外科杂志,2014,29(10):882-883.
[21]罗智辉,陈卓荣.吡柔比星联合长春瑞滨治疗晚期乳腺癌的疗效观察[J].北方药学,2015,12(4):29-30.
[22]冯凌飞,贺曾.右丙亚胺对联用吡柔比星化疗患者的心脏保护作用[J].中国肿瘤外科杂志,2014,6(5):292-293.
[23]张爱良,刘芳.多西他赛合吡柔比星治疗老年晚期乳腺癌48例临床疗效观察[J].中国民族民间医药,2013,18(1):96-97.
[24]杨志峰,刘超,刘晓燕,等.吡柔比星与柔红霉素分别联合阿糖胞苷治疗急性早幼粒细胞白血病的疗效对比研究[J].西部医学,2014,26(10):1268-1270.
[25]王琳,孙宝兰,张国华,等.丙戊酸钠联合吡柔比星对儿童急性淋巴细胞白血病细胞株的作用[J].南通大学学报(医学版),2014,34(4):278-282.
[26]玄承敏,薛天阳,许伟.环磷酰胺和吡柔比星对横纹肌肉瘤RD细胞株CXCR4表达的影响[J].中国小儿血液与肿瘤杂志,2014(3):129-133.
[27]林思文,殷嫦嫦,殷明,等.淫羊藿总黄酮与吡柔比星联合抗人骨肉瘤的作用机制[J].中国医院药学杂志,2015,35(2):108-112.
[28]张冬华,孙建群.硼替佐米联合吡柔比星、地塞米松治疗初治多发性骨髓瘤14例临床分析[J].中国药业,2015, 24(1):78-80.
[29]虞欢东,于海涛,夏建国,等.顺铂联合吡柔比星对脑胶质瘤U87细胞株增殖的抑制作用[J].中国现代医生,2014,52(15):1-3.
[30]陈莹,梁玉梅.α-干扰素联合吡柔比星治疗尿毒症合并膀胱癌的临床疗效观察[J].肿瘤药学,2013, 3(5):372-374.
[2]Kudo K,Kojima S,Tabuchi K,et al. Prospective study of a pirarubicin,intermediate-dose cytarabine,and etoposide regimen in children with Down syndrome and acute myeloid leukemia:the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol,2007,25(34):5442-5447.
[3]Robert J,Monnier A,Poutignat N,et al. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients[J]. Cancer Chemother Pharmacol,1991,29(1):75-79.
[4]Ito A,Shintaku I,Satoh M,et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin(THP)in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma:the THP Monotherapy Study Group Trial[J]. J. Clin. Oncol,2013,31(11):1422-1427.
[5]YamamotoY,NasuY,SaikaT,etal.Theabsorptionof pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer[J]. BJU Int,2000,86(7):802-804.
[6]杨玉龙,宋炳生.新型抗肿瘤药吡柔比星(THP)国内临床应用概况[J].华西药学杂志,1998,13(3):168-174.
[7]Li K,Chen X,Liu C,et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells[J]. Biochem Biophys Res Commun,2015,460(2):380-385.
[8]葛波,宋亚辉,张旭,等.吡柔比星诱导人膀胱癌T24细胞凋亡及其作用机制[J].中华实验外科杂志,2014,31(10):2235-2237.
[9]欧俐苹,杜红飞,吕长坤,等.吡柔比星通过PLCε-Bcl-2通路抑制膀胱癌细胞增殖[J].第二军医大学学报,2014,35(7):708-713.
[10]李鹏程,李飞,宋亚辉,等.吡柔比星对膀胱癌EJ细胞增殖及Livin和Caspase-3表达的影响[J].医学研究生学报,2015,28(3):255-259.
[11]卜强,曾明辉,蒋华,等.吡柔比星联合雷公藤甲素对人膀胱癌T24细胞生长的影响[J].肿瘤,2014,34(6):514-519.
[12]吕长坤,万雪莲,马菲菲,等. HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖[J].重庆医科大学学报,2015,40(2):234-238.
[13]宋兆录,刘镇,彭传真,等.术中黏膜下注射与术后即刻灌注吡柔比星预防表浅性膀胱癌术后复发的疗效比较[J].现代泌尿外科杂志,2011,16(1):45-46.
[14]陶炅华,江秀.吡柔比星联合羟基喜树碱对预防膀胱癌电切术后复发的疗效[J].检验医学与临床,2015,12(4):546-547.
[15]蓝汉荣,胡万胜.不同手术方案联合吡柔比星膀胱灌注化疗在浅表性膀胱癌患者中的应用比较[J].中国当代医药,2015,22(8):68-70.
[16]丁宝军,刘成,刘多,等.二次电切联合盐酸吡柔比星膀胱灌注治疗高危非肌层浸润性膀胱尿路上皮癌疗效观察[J].现代医药卫生,2014,30(19):2908-2910.
[17]武广平,秦玉波,乔卫东,等.吡柔比星膀胱灌注联合腔镜技术对膀胱继发性原位癌定位诊断及治疗的效果观察[J].山东医药,2011,51(46):47-48.
[18]王磊,刘致中,赵海涛,等.非肌层浸润性膀胱癌TURBT术后黏膜下注射吡柔比星联合丝裂霉素灌注的疗效观察[J].临床泌尿外科杂志,2014,29(2):125-127.
[19]张冲,杨鹏,刘振湘. RevoLix 2μm激光联合吡柔比星在非肌层浸润性膀胱癌治疗中的应用[J].现代泌尿生殖肿瘤杂志,2014,6(3):137-139.
[20]厉波,厉彦卓,武广平,等.高能聚焦超声联合吡柔比星姑息性治疗膀胱癌(附18例报告)[J].临床泌尿外科杂志,2014,29(10):882-883.
[21]罗智辉,陈卓荣.吡柔比星联合长春瑞滨治疗晚期乳腺癌的疗效观察[J].北方药学,2015,12(4):29-30.
[22]冯凌飞,贺曾.右丙亚胺对联用吡柔比星化疗患者的心脏保护作用[J].中国肿瘤外科杂志,2014,6(5):292-293.
[23]张爱良,刘芳.多西他赛合吡柔比星治疗老年晚期乳腺癌48例临床疗效观察[J].中国民族民间医药,2013,18(1):96-97.
[24]杨志峰,刘超,刘晓燕,等.吡柔比星与柔红霉素分别联合阿糖胞苷治疗急性早幼粒细胞白血病的疗效对比研究[J].西部医学,2014,26(10):1268-1270.
[25]王琳,孙宝兰,张国华,等.丙戊酸钠联合吡柔比星对儿童急性淋巴细胞白血病细胞株的作用[J].南通大学学报(医学版),2014,34(4):278-282.
[26]玄承敏,薛天阳,许伟.环磷酰胺和吡柔比星对横纹肌肉瘤RD细胞株CXCR4表达的影响[J].中国小儿血液与肿瘤杂志,2014(3):129-133.
[27]林思文,殷嫦嫦,殷明,等.淫羊藿总黄酮与吡柔比星联合抗人骨肉瘤的作用机制[J].中国医院药学杂志,2015,35(2):108-112.
[28]张冬华,孙建群.硼替佐米联合吡柔比星、地塞米松治疗初治多发性骨髓瘤14例临床分析[J].中国药业,2015, 24(1):78-80.
[29]虞欢东,于海涛,夏建国,等.顺铂联合吡柔比星对脑胶质瘤U87细胞株增殖的抑制作用[J].中国现代医生,2014,52(15):1-3.
[30]陈莹,梁玉梅.α-干扰素联合吡柔比星治疗尿毒症合并膀胱癌的临床疗效观察[J].肿瘤药学,2013, 3(5):372-374.